AC
ADAP

Almitas Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Almitas Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-109,054
Closed -$26.1K – 67
2025
Q2 		$26.1K Buy
+109,054
New +$29.1K 0.01% 81

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Almitas Capital's ADAP Position: Q3 2025 in Review

Almitas Capital sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 109,054 shares — an estimated $26.1K sold.

Almitas Capital first reported a position in ADAP in Q2 2025 and held it in 1 quarter. The position peaked at $26.1K in Q2 2025. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • Almitas Capital reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Almitas Capital sold 109,054 Adaptimmune Therapeutics shares in Q3 2025, an estimated $26.1K.
  • Almitas Capital first reported a position in Adaptimmune Therapeutics in Q2 2025 and held it in 1 quarter.
  • Almitas Capital's Adaptimmune Therapeutics position peaked at $26.1K in Q2 2025.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Almitas Capital's 13F filing for Q3 2025, filed 14 Nov 2025.